• Nexalin reported results from a completed open-label clinical trial in Brazil testing its non-invasive neurostimulation protocol in adults with anxiety.
• The study showed broad symptom improvement with benefits that held through follow-up, supporting the case for durable clinical effect.
• Outcomes also pointed to improvements in related depression and sleep problems, alongside better reported quality of life.
• Tolerability appeared favorable, with no serious safety issues flagged in the trial readout.
• The results are being used to support a planned product launch and sales rollout in Brazil.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100915PRIMZONEFULLFEED9734783) on June 10, 2026, and is solely responsible for the information contained therein.